FDA 483 - Anish Shah, M.D. - September 15, 2025

Siyan Clinical Research in Santa Rosa, CA, was inspected as a clinical investigator. The inspection revealed a significant issue with the conduct of an investigation, specifically a failure to maintain rater blinding as required by the investigational plan. This indicates a deviation from proper study execution protocols.